Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low-birth-weight infants

Pediatric Critical Care Medicine

Volumn 7, Issue 2, 2006, Pages 143-146

  Allegaert, Karel ^a   Debeer, Anne ^a   Cossey, Veerle ^a   Rayyan, Maissa ^a   Devlieger, Hugo ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amikacin; Dopamine; Extremely low birth weight infants; Variability

Indexed keywords

AMIKACIN; AMPICILLIN; BETAMETHASONE; DOPAMINE; IBUPROFEN; INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; ASSISTED VENTILATION; BACTERIAL INFECTION; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; EXTREMELY LOW BIRTH WEIGHT; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

AMIKACIN; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CARDIOTONIC AGENTS; CYCLOOXYGENASE INHIBITORS; DOPAMINE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; METABOLIC CLEARANCE RATE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 33645547754     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000200971.65255.F0     Document Type: Article

References (17)

1. Allegaert K, Cossey V, Langhendries JP, et al: Effects of co-administration of ibuprofenlysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 2004; 86:207-211
2. Allegaert K, Vanhole C, de Hoon J, et al: Nonselective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates. Pediatr Nephrol 2005; 20:1557-1561
3. Cuevas L, Yeh TF, John EG, et al: The effect of low-dose dopamine infusion on cardiopulmonary and renal status in premature newborns with respiratory distress syndrome. Am J Dis Child 1991; 145:799-803
4. Lynch SK, Lemley KV, Polak MJ: The effect of dopamine on glomerular nitration rate in normotensive, oliguric premature neonates. Pediatr Nephrol 2003; 18:649-652
5. Seri I, Rudas G, Bors Z, et al: Effects of low-dose dopamine infusion on cardiovascular and renal functions, cerebral blood flow, and plasma catecholamine levels in sick preterm neonates. Pediatr Res 1993; 34:742-749
6. Barrington K, Brion LP: Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. Cochrane Database Syst Rev 2002; 3:CD003213
7. Van den Anker JN: Renal function and excretion of drugs in the newborn. In: Yaffe SJ, Aranda JV (Eds). Neonatal and Pediatric Pharmacology, Third Edition. Philadelphia, Lipponcott Williams & Wilkins, 2005, pp 172-186
8. Koren G, James A, Perlman M: A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther 1985; 38:680-685
9. Zarowitz BJ, Robert S, Peterson EL: Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother 1992; 26:1205-1210
10. Vanhole C, Jannes F, Vrancken M, et al: Continuous infusion of medications in very low birth weight infants. Eur J Clin Pharmacol 2004; 60:383-386
11. van Overmeire B, Allegaert K, Casaer A, et al: Prophylactic ibuprofen in premature infants: A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:1945-1949
12. Langhendries JP, Battisti O, Bertrand JM, et al: Adaptation in neonatology of the one-daily concept of aminoglycoside administration: Evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998; 74:351-362
13. Guignard JP, Drukker A: Why do newborn infants have a high plasma creatinine? Pediatrics 1999; 103:e49
14. Bleyzac N, Varnier V, Labaune JM, et al: Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol 2001; 57:499-504
15. Guignard JP: The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002;26:398-405.
16. Matthews I, Kirkpatrick C, Holford N: Quantitative justification for target concentration intervention: Parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. Br J Clin Pharmacol 2004; 58:8-19
17. Allegaert K, Anderson B, Cossey V, et al: Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 2006; 61:39-48